Tc-99m HMDP bone scintigraphy for cardiac amyloidosis diagnosis: A false positive case

Guillaume Lades (1) , Hélène Carpenet (1) , Unvoy Benoit (1) , Victor Aboyans (2, 3) , Jacques Monteil (1)

1 Service de médecine nucléaire [CHU Limoges]
2 NET - Neuroépidémiologie Tropicale
3 Service de cardiologie [CHU Limoges]

A 68-year-old man with heart failure (left ventricular ejection fraction = 30%) and normal coronary angiography underwent bone scintigraphy for suspected transthyretin-related cardiac amyloidosis (CA).1 He received 532 MBq (14.3 mCi) Tc-99m hydroxy-methyl-diphosphonate (HMDP) and data were acquired 2 hours after injection. On anterior and posterior whole-body scans (Figure 1 A and B), diffuse cardiac, hepatic, and soft-tissue uptake of the radiotracer was seen, in association with low skeletal uptake. It was established that the patient had recently been hospitalized for heart failure exacerbation and had received an intravenous iron injection, which is a recommended treatment for heart failure.2 In consultation with our hospital's cardiology team, it was decided to repeat the bone scan at a time when the patient had received no recent iron infusion. Two months after the first bone scan, the patient received 556 MBq (15 mCi) of 99m-Tc HMDP, and no cardiac, hepatic, or soft-tissue uptake was detected (Figure 1C and D).

Mots clés: Amyloid heart disease; Molecular imaging; SPECT

Domaines: Santé publique et épidémiologie

Guillaume Lades, Hélène Carpenet, Unvoy Benoit, Victor Aboyans, Jacques Monteil. Tc-99m HMDP bone scintigraphy for cardiac amyloidosis diagnosis: A false positive case. Journal of Nuclear Cardiology, 2021, ⟨10.1007/s12350-020-02451-3⟩. ⟨hal-03448150⟩